Physician profile
Soon Kim
NPI 1023095643
$20,696.75
in general payments reported to CMS, 2019-2025
41 companies · $80.94 in 2025
The $80.94 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,191 · 2020: $2,753 · 2021: $4,545 · 2022: $2,573 · 2023: $2,500 · 2024: $1,054 · 2025: $80.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,461 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,461.01 |
| Education | $173.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,394.04 | 2019-2025 | Farxiga, Airsupra, Tezspire |
| Novo Nordisk INC | $1,939.24 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $1,708.14 | 2019-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,148.23 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,128.26 | 2019-2021 | |
| Lilly USA, LLC | $1,062.83 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $1,050.85 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $764.72 | 2019-2023 | |
| Esperion Therapeutics, INC. | $761.38 | 2021-2023 | Nexletol |
| Abbvie INC. | $751.91 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $733.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $646.17 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $592.52 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $571.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $487.53 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soon Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.